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Analysis of the eﬀects of cyclosporine A (25–28mgkg
−1) and/or methotrexate (0.1mgkg
−1) treatments on dipeptidyl peptidase IV
(DPPIV) and prolyl oligopeptidase (POP) activities and on algesic response in two distinct status of murine macrophages (Mφs)
was undertaken. In resident Mφs, DPPIV and POP were aﬀected by neither individual nor combined treatments. In thioglycolate-
elicited Mφs, methotrexate increased DPPIV (99–110%) and POP (60%), while cyclosporine inhibited POP (21%). Combined
treatment with both drugs promoted a rise (51–84%) of both enzyme activities. Only cyclosporine decreased (42%) the tolerance
to algesic stimulus. Methotrexate was revealed to exert prevalent action over that of cyclosporine on proinﬂammatory Mφ POP.
T h eo p p o s i t ee ﬀects of methotrexate and cyclosporine on POP activity might inﬂuence the availability of the nociceptive medi-
ators bradykinin and substance P in proinﬂammatory Mφs. The exacerbated response to thermally induced algesia observed in
cyclosporine-treated animals could be related to upregulation of those mediators.
Copyright © 2008 R. A. Olivo et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Macrophage (Mφ) is considered the main eﬀector cell type
of the immune system. Under stimulation, this cell is ac-
tivated by a process involving morphological, biochemical,
and functional changes [1]. Among the relevant enzyme ac-
tivities on Mφ functions are the membrane-bound (M) and
soluble(S)dipeptidylpeptidaseIV(DPPIV)andtheSprolyl
oligopeptidase(POP)[2].DPPIVcleavessubstanceP[3]and
inﬂammatory mediators such as interferon-gamma (IFNγ),
chemokines and proinﬂammatory cytokines [4], while POP
cleaves the nociceptive mediators bradykinin and substance
P[ 5]. During inﬂammation, nonneuronal cells such as Mφ
produce a variety of chemical mediators that can act on no-
ciceptive neurons [6]. On the other hand, nociceptive medi-
ators such as bradykinin [7, 8] and substance P [9, 10]a c to n
the immune response and Mφ functions.
Methotrexate (MTX) and cyclosporine (CsA) are im-
munomodulators that belong to the most commonly used
group of drugs for cytotoxic therapy. However, their ex-
act mechanisms of action are not yet clariﬁed. Although
MTX and CsA have been used alone [11] or in a combined
therapy [12] for inﬂammatory and painful chronic disease
treatments, experimental and clinical studies are needed to
determine the extent to which MTX and CsA treatments
aﬀect the Mφ functions and, more speciﬁcally, its pepti-
dases with hydrolytic ability on inﬂammatory and noci-
ceptive mediators. It is known that Mφs functions are un-
changed or reduced in the presence of CsA. The reduction
includes in vitro interleukin-1 generation [13], chemotaxis
[14], prostaglandin E2 production [15], procoagulant ac-
tivity [16], and major histocompatibility complex (MHC)
[17] and inducible nitric oxide synthase [18] expressions.
CsAalsoreducesphorbol12-myristate13-acetate-dependent
superoxide anion and H2O2 production in vitro by resi-
dent (RE) murine Mφs, which are abolished when Mφs
are in the proinﬂammatory state [19]. MTX, but not CsA,
is able to enhance in vitro spreading of murine peritoneal
Mφs[ 20]. MTX is also known to inhibit production of
cytokines induced by T-cell activation. Interleukin (IL)-4,
IL-13, IFN gamma, tumor necrosis factor-alpha (TNFα)
and granulocyte-macrophage colony-stimulating factor are
among the cytokines inhibited by MTX [21].
The ex vivo isolated RE and thioglycollate broth
medium-elicited (TGE) Mφ models mimic, respectively, the
in vivo basal and proinﬂammatory status of this cell. The2 Clinical and Developmental Immunology
proinﬂammatory Mφs are present in acute and chronic in-
ﬂammation as major players in the generation and release
of a variety of inﬂammatory and nociceptive mediators. A
possible relationship between the ex vivo TGE Mφ DPPIV
and POP activity levels with the in vivo excitability to ther-
mal pain stimulus could highlight the in vivo role of these
peptidases through their actions on those inﬂammatory and
nociceptive mediators after their generation and release by
Mφs in inﬂammatory and painful diseases. This study aims
to analyze the interference of MTX and CsA, each one daily
administered alone or combined during 21 days, on the ac-
tivity levels of S DPPIV and POP, and MDPPIV in two dis-
tinct status of ex vivo isolated peritoneal murine Mφs—the
noninﬂammatory RE and the proinﬂammatory TGE cells—
as well as whether the excitability to thermal pain stimulus
could be altered by these drugs or correlated to Mφ status
and peptidase activities.
2. MATERIALS AND METHODS
2.1. Animalsandtreatments
Healthy Swiss strain mice, males, weighing 18–20g, were
maintained in a restricted-access room with controlled tem-
perature of 25◦C, relative humidity of 65.3 ± 0.9%, and 12
h light:12 h dark photoperiod (lights on at 6:00 am), and
were housed in cages (inside length × width × height of
56 × 35 × 19cm) with a maximum of 20mice per cage, with
food and tap water ad libitum.
Animals were subcutaneously (s.c.) injected, once a day,
with50μL of cyclosporine A (CsA) (10mg CsA/mL ricine oil
(starting dose: 25–28mg/kg BW) or of ricine oil (control),
during 21 days. Other groups were administered by gavage
(p.o.) of 0.2mL, once a day, with methotrexate (MTX) dis-
solved in saline 0.9% (starting dose: 0.1mg/kg BW) or with
saline (control), during 21 days. A fourth group and its cor-
responding control were simultaneously submitted to treat-
ments with both drugs and both vehicles, respectively, in the
same scheme as described above. Subsequently, Mφsw e r e
collected from individuals of each group (treated and con-
trols of MTX and/or CsA). The regimen of treatment with
MTX [22] and/or CsA [23] used in this study was chosen by
its well-known immunosuppressive eﬀect.
The animal and research protocols used in this study are
in agreement with the Brazilian Council Directive (COBEA-
BRAZIL) and were approved by the Ethics Committee of the
Instituto Butantan.
2.2. Hot-platenociceptivetest
This test was employed based on the method of Jacob and
Ramabadran [24]. Mice were placed on a metal surface kept
at 64.5
◦C ± 0.5
◦C. Results are expressed as the latency time
to the observed licking of both anterior feet (latency of re-
sponse).
2.3. ObtentionofREandTGEmacrophages
The peritoneal lavage was performed in half of each group
(treated and controls of MTX and/or CsA) after a gentle
massage of the abdominal wall. Then, the peritoneal ﬂuid,
containing Mφs, was collected. Aliquots of the washes were
used to determine the total number of peritoneal cells in a
Neubauer’s chamber after dilution (1:20, v/v) in Turk solu-
tion (0.002g gentian violet in 500mL 3% acetic acid). The
predominance of mononuclear cells in the washes was con-
ﬁrmed by light microscopic analysis of smears stained with
Hema3. The cell population consisted in proximally 99% of
Mφs, as determined by morphological criteria. Washes were
then centrifuged at 200Xg,6m i n u t e s ,2 2 ◦C, and the pellet
obtained resuspended in 2.0mL of 10mM Tris-HCl, pH 7.4.
The other half of each group was also submitted to peri-
toneal lavage, which was performed, according to the above
description, 4 days after IP administration of 1.0mL of 3%
thioglycollatebrothmedium(TG).Thecellpopulationinthe
washes of these TG-treated mice consisted of more than 95%
of Mφs, as determined by morphological criteria.
The number of obtained Mφsf r o mp e r i t o n e a ll a v a g e
was about 4 × 106/mL in TG-treated (TGE-Mφs) and about
1 × 106/mL in mice that are not treated with TG (RE Mφs).
There were no diﬀerences in Mφ number among groups
treated with MTX and/or CsA and/or vehicles.
All animals were killed under halothane and exsan-
guinated immediately before these procedures.
2.4. Preparationofthesoluble(S)andsolubilized
membrane-bound(M)fractions
Mφ suspensions in 10mM Tris-HCl buﬀer, pH 7.4 were son-
icated at room temperature at amplitude 40 for 10 seconds.
Sonicated Mφs were then ultracentrifuged (Hitachi model
HIMAC CP60E) at 165000 X g for 35 minutes. The result-
ing supernatants were used to measure the S enzyme activi-
tiesandproteinconcentrations.Toavoidcontaminationwith
theS,theresultingpelletwaswashedthreetimeswith10mM
Tris-HClbuﬀer,pH7.4.Thepelletwasthenhomogenizedfor
30secondsat800rpm(Contracpestlemixer,FANEN,Brazil)
in 10mM Tris-HCl buﬀer, pH 7.4, plus 0.1% Triton X-100
and ultracentrifuged at 165000 X g for 35 minutes. The su-
pernatants obtained were used to determine the M enzyme
activities and protein concentrations. All steps were carried
out at 4◦C.
As a marker for the fractionation procedure, LDH activ-
ity was determined spectrophotometrically at 340nm [25]i n
the S and M fractions of Mφs from all treated and control
groups. Brieﬂy, samples of 30uL of S and M from Mφsw e r e
incubated with 270uL of 100mM phosphate buﬀer, pH 7.4,
containing 200mM NaCl and 1.6mM sodium pyruvate so-
lution plus 0.2mM nicotinamide adenine dinucleotide, re-
duced form (NADH) disodium salt. Values of LDH activity
were obtained by the results of subtraction of the absorbance
at340nmreadat10minutesfromthatreadat0timeofincu-
bation at 37◦C, and extrapolated by comparison with a stan-
dardcurveofNADH.Student’st-testwasperformedtocom-
pare the results of LDH between S and M fractions. The lev-
els of LDH activity were similar to those previously reported
[2], being higher in S than in M fractions (data not shown),
which conﬁrmed the eﬃciency of the adopted fractionationR. A. Olivo et al. 3
Table 1: Dipeptidyl peptidase IV (DPPIV) and prolyl oligopeptidase (POP) activities in soluble (S) and membrane-bound (M) fractions
of resident (RE) and thioglycollate-elicited (TGE) macrophages from vehicle-treated animals (ricine oil s.c.=controls of cyclosporine; saline
p.o.=controls of methotrexate; ricine oil s.c. plus saline p.o.=controls of methotrexate plus cyclosporine).
Vehicle Enzyme
Activity (UP/mg protein)
SM
RE TGE RE TGE
Ricine oil
DPPIV
334 ±42 359 ±53∗ 112 ±7 112 ±26
Saline 391 ±67 174 ±35a 145 ±43 73 ±12
Ricine oil + saline 319 ±23 357 ±13∗∗ 605 ±50∗∗∗ 355 ±53∗∗∗b
Ricine oil
POP
278 ±16 200 ±10∗∗c absent
Saline 286 ±44 133 ±8b absent
Ricine oil + saline 320 ±23 343 ±18∗∗∗ absent
UP=picomoles substrate hydrolyzed per minute. Values are means ± SEM from 5 animals (assays made in triplicate). Comparisons among vehicle treatments
regarding the same enzyme activity in each fraction and macrophage status (analysis of variance, ANOVA, followed by SNK test): ∗P<. 05, ∗∗P<. 01 versus
saline; ∗∗∗P<. 001 versus saline or ricine oil. Comparisons between TGE versus RE related to the same enzyme activity in each fraction and vehicle treatment
(unpaired two-sided Student’s t-test): aP<. 03, bP<. 01, cP<. 005.
procedure. Moreover, these levels were not altered by MTX
and/or CsA and/or vehicles treatments (data not shown).
2.5. Protein
P r o t e i nc o n c e n t r a t i o n sw e r em e a s u r e di n4 0 - u Ls a m p l e sa t
630nm by Bradford [26] method using Bio-Rad protein as-
say kit. Absorbance was read using the Bio-Tek Power Wave
X spectrophotometer. Protein contents were extrapolated
by comparison with respective standard curves of bovine
serum albumin (BSA).
2.6. Peptidaseassays
Peptidase activities were quantiﬁed on the basis of the
amount of 4-methoxy-β-naphthylamine (for DPPIV) or β-
naphthylamine (for POP) released as a result of the enzy-
matic activity of undiluted 50-uL samples of the S or M frac-
tions from Mφs incubated at 37◦C for 30 minutes in 96-
well ﬂat botton microplates (Corning Inc., USA) with 250uL
of each respective prewarmed substrate solution diluted
to 0.2mM (DPPIV) or 0.125mM (POP) in corresponding
0.05MbuﬀerscontainingBSA0.1mg/mL.β-Naphthylamine
or 4-methoxy-β-naphthylamine were estimated ﬂuoromet-
rically using the Bio-Tek FL600FA Microplate Fluores-
cence/AbsorbanceReader,at460/40nmemissionwavelength
and 360/40nm excitation wavelength in triplicate samples.
The value of incubates at zero time (blank) was subtracted
and the relative ﬂuorescence was converted to picomoles of
4-methoxy-β-naphthylamine or β-naphthylamine by com-
parison with a correspondent standard curve. Peptidase ac-
tivity was expressed as picomoles of substrate hydrolyzed
per minute (UP) per milligram of protein. Assays were lin-
ear with respect to time of hydrolysis and protein content.
DPPIV activity was measured by the method of Liu and
Hansen [27] using H-Gly-Pro-4-methoxy-β-naphthylamide
in Tris-HCl buﬀer, pH 8.3. POP activity was measured by
the method of Zolfaghari et al. [28] using Z-Gly-Pro-β-
naphthylamide in phosphate buﬀe r ,p H7 . 4 ,w i t h2 m M
dithiothreitol (DTT), without or with diﬀerent concentra-
tions of Z-Pro-Pro-OH (Z-pro-prolinal).
2.7. Materials
Commercially available cyclosporine A (Sandimmun,
Novartis, Brazil), methotrexate (Metrexato,B l a ¨ usiegel,
Brazil), ricine oil (Sidepal, Brazil), Bio-Rad protein assay
kit (Hercules, USA), Gly-Pro-4-methoxy-β-naphthylamide
(Peninsula, USA), Z-Gly-Pro-β-naphthylamide, Z-Pro-Pro-
OH (Bachem, USA) and Hema3 (Fisher Sci, USA). Bovine
serum albumin, β-naphthylamine, gentian violet (crystal vi-
olet), halothane, 4-methoxy-β-naphthylamine, dithiothre-
itol, nicotinamide adenine dinucleotide, reduced form, dis-
odium salt and sodium pyruvate were from Sigma, USA. All
other reagents of analytical grade were from Merck, Brazil.
2.8. Statisticalanalysis
The data were analyzed statistically using GraphPad Prism
and Instat softwares. Regression analyses were performed
to obtain standard curves. Analysis of variance, ANOVA, was
performed to compare values of the same enzyme activity
from S or M among control groups, and to compare the val-
ues of POP activity under diﬀerent concentrations of Z-pro-
prolinal inhibitor. It was followed by student-newman-keuls
test (SNK) when diﬀerences were detected. Student’s t-test
was performed to compare the values of the same parame-
ters between RE and TGE Mφs in each control group or be-
tween control and MTX- and/or CsA-treated animals on day
21, and to compare the values of latency of response-induced
algesia between control and MTX- and/or CsA-treated ani-
mals along the treatments. Diﬀerences were considered sta-
tistically signiﬁcant at a minimum level of P<. 05.4 Clinical and Developmental Immunology
0
20
40
60
80
100
1 5 25 50
×10−4
Concentration (M)
I
n
h
i
b
i
t
i
o
n
(
%
) ∗∗
∗
Figure 1: Eﬀect of Z-pro-prolinal on soluble prolyl oligopeptidase
activity of thioglycollate-elicited murine macrophages. The values
(means ± SEM from 5 animals) were recorded in triplicate as the
percentage of inhibition relative to control reactions (enzyme activ-
ity=100%, percentage of inhibition=0) which run simultaneously
in absence of Z-pro-prolinal. All concentrations of Z-pro-prolinal
produced lower levels of enzyme activity when compared to the
control (unpaired two-sided Student’s t-test, P<. 05). ∗P<. 05 in
comparisonto5×10
−4 Mor25×10
−4 M;∗∗P<. 001incomparison
to all other concentrations of Z-pro-prolinal (analysis of variance,
ANOVA, followed by SNK test).
3. RESULTS
Table 1 shows the peptidase activity levels of S and M frac-
tions from RE and TGE Mφso fd i ﬀerent controls. Saline
per oral (p.o.) produced 1.5 to 2.5-fold reduction in soluble
DPPIV and POP activities of TGE Mφs when compared to
ricineoils.c.ortoricineoils.c.plussaline(p.o.).Membrane-
bound DPPIV activity in TGE Mφs was also 4.8-fold lower
after saline p.o. than after ricine oil plus saline treatment,
which in this turn was 3.2-fold higher than after ricine oil s.c.
administeredalone.InREMφs,activitylevelsofbothsoluble
DPPIVandPOPobtainedafterallschemesofvehicleadmin-
istration did not vary signiﬁcantly, while membrane-bound
DPPIV was about 5-fold higher after ricine oil plus saline
treatment than ricine oil or saline administered alone. Com-
parisons between RE and TGE Mφs in each regimen of vehi-
cle administration also revealed that soluble DPPIV activity
of TGE Mφs was about 2-fold lower than RE Mφsf r o ma n -
imals that received saline p.o. treatment. Membrane-bound
DPPIV activity of TGE Mφs was 1.7-fold lower than RE Mφs
from animals that received treatment with combined vehi-
cles. Ricine oil s.c. or saline p.o administered alone produced
a drop between 1.3 to 2.1 on POP activity levels of TGE Mφs
compared to RE Mφs.
DPPIV activity of Mφs was previously demonstrated to
be inhibited by diprotin A, a classical inhibitor of the canon-
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Figure 2: Latency of response-induced algesia of mice treated with
methotrexate (MTX) and/or cyclosporine (CsA), or with ricine oil
plus saline (control). Values are means ± SEM from 10–14 animals.
∗P<. 001 in comparison to control (unpaired two-sided Student’s
t-test).
ical DPPIV [2]. Since POP activity of Mφs was surprisingly
inhibited by classical aminopeptidase inhibitors [2], its sus-
ceptibility to a classical POP inhibitor, Z-pro-prolinal, was
checked in the present study. As shown in Figure 1, POP ac-
tivity of Mφs was inhibited (58–91%) by Z-pro-prolinal at
the employed concentrations (1 to 50 ×10
−4M).
As shown in Figure 2, administration of vehicles, or
MTX, or MTX plus CsA produced a similar reaction time to
that of the thermal stimulus. On day 21, the administration
of CsA alone decreased 0.58-fold of the reaction time when
compared to the values obtained after the treatment with the
combined vehicles.
Figure 3 shows that MTX treatment resulted in a signif-
icant rise of soluble activity levels of DPPIV (2.1-fold) and
POP (1.6-fold) in the TGE Mφs when compared to those ob-
served after the treatment with the respective vehicle. MTX
treatment also resulted in a signiﬁcant rise in membrane-
bound DPPIV activity levels (2-fold) in TGE Mφs when
compared to those observed after treatment with its respec-
tive vehicle (see Figure 3).
Figure 4 shows that CsA treatment resulted in a drop of
POP activity levels (0.79-fold) in the TGE Mφs when com-
pared to those observed after the treatment with the respec-
tive vehicle. However, CsA treatment did not change the ac-
tivity levels of soluble or membrane-bound DPPIV when
compared to those observed after the treatment with the re-
spective vehicle (see Figure 4).
As shown in Figure 5, combined treatment with MTX
and CsA promoted an increase in activity levels of soluble
(1.5-fold) and membrane-bound (1.8-fold) DPPIV and sol-
ublePOP(1.8-fold)intheTGEMφswhencomparedtothose
observed after treatment with the combined vehicles.
Figure 4 shows that CsA treatment resulted in a drop
of POP activity levels (0.79-fold) in the TGE Mφs when
compared to those observed after the treatment with theR. A. Olivo et al. 5
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Figure 3: Percentual activity of soluble and membrane-bound dipeptidyl peptidase IV (DPPIV) and prolyl oligopeptidase (POP) activities
in resident and thioglycollate-elicited murine macrophages from methotrexate-treated in relation to their respective controls (100%). Values
are means ± SEM from 5 animals (assays made in triplicate). ∗P<. 001 in comparison to control (unpaired two-sided Student’s t-test).
respective vehicle. However, CsA treatment did not change
the activity levels of soluble or membrane-bound DPPIV
when compared to those observed after the treatment with
the respective vehicle (see Figure 4).
4. DISCUSSION
The intraperitoneal injection of TG increased about four
times the obtained Mφ number from all treatment groups
(MTX and/or CsA and/or vehicles), after 4 days. However,
the expression of enzyme activity adopted in the present
study might not be correlated to cell number, since it was
normalized by mg of protein in the cell homogenates, that
is, enzyme activity = picomoles substrate hydrolyzed per mg
of protein. As expected we detected stress-induced eﬀects of
adopted administration regimens on the activity levels of ex-
amined Mφ peptidases. It is well-known that in response to
certain physical stressors the release of neuropeptides from
sensory nerves is increased, mainly substance P (or other in-
ﬂammatory mediators), and in this turn, these neuropep-
tides promote the activation of Mφs[ 29]. It is noteworthy
that DPPIV and POP presented higher activity levels in S
and/orMfractionsofREandTGEMφsfr ommicesubmitted
to chronic s.c. (ricine oil treatment) and/or p.o. (saline treat-
ment) administrations than those obtained without these
stress stimuli [2]. However, in relation to s.c. regimen or to
RE Mφs, inducible stress by p.o. regimen reduced the incre-
ment of peptidase activities in TGE Mφs. Overall, apart from
these variations among diﬀerent controls adopted in the
present study, we elucidate that the regimen of MTX and/or
CsA treatments diﬀerentially aﬀected DPPIV and POP ac-
tivities of murine Mφs, an eﬀect that only occurred under
elicited (or proinﬂammatory) status of these cells. The eﬀect
of MTX on DPPIV activity of proinﬂammatory TGE Mφs
but not on RE Mφs suggested that DPPIV activity is rele-
vant to the immunosuppressor/anti-inﬂammatory actions of
MTX. MTX and CsA had opposite eﬀects on POP activity of
TGE Mφs ,s u g g e s t i n gad r o po fh y d r o l y t i ca c t i v i t yo fT G E
Mφ POP on pain mediators. Since TGE Mφsa r eam o d e l
of proinﬂammatory Mφs and these cells are abundant in in-
ﬂammatory processes, and the nervous system inﬂuences the
peripheralinﬂammatoryprocess,itisconceivablethatthere-
ductionofPOPactivityparticipatesinthedevelopmentofal-
gesic hyperexcitability in CsA therapy. However, this algesic
hyperexcitability could be attributed to an eﬀect on the ner-
vous system through which CsA treatment exacerbates the
reaction to this stimulus. In this case, the altered reaction to
acute thermal algesic stimulus might have an indirect partic-
ipation of Mφs.
Changes on the activity levels of DPPIV-like enzyme(s)
in TGE Mφs due to MTX treatment were particularly rele-
vant, as these might participate within the pharmacological6 Clinical and Developmental Immunology
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Figure 4: Percentual activity of soluble and membrane-bound dipeptidyl peptidase IV (DPPIV) and prolyl oligopeptidase (POP) activities
in resident and thioglycollate-elicited murine macrophages from cyclosporine-treated in relation to the respective control (100%). Values
are means ± SEM from 5 animals (assays made in triplicate). ∗P<. 05 in comparison to control (unpaired two-sided Student’s t-test).
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Figure 5: Percentual activity of soluble and membrane-bound dipeptidyl peptidase IV (DPPIV) and prolyl oligopeptidase (POP) activities
in resident and thioglycollate-elicited murine macrophages from methotrexate plus cyclosporine-treated in relation to the respective control
(100%). Values are means ± SEM from 5 animals (assays made in triplicate). ∗P<. 001 in comparison to control (unpaired two-sided
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action of MTX through an increased ability of this cell to in-
activateseveralsusceptiblesubstratesknowntobeinﬂamma-
tory and/or immunological mediators. However, since MTX
increasedDPPIVactivityinTGEMφsbutdidnotmodifythe
reaction to the algesic stimulus, it is likely that this reaction
is not related to an increased hydrolysis of substance P by
this enzyme. Alternatively, only the reduction of DPPIV ac-
tivity below a critical level, as observed here for POP activity
of TGE Mφs from mice treated with CsA, could be related to
hyperalgesia. DPPIV-like enzyme(s) exert diﬀerent functions
regarding cell type and intra- or extracellular conditions in
which they are expressed [30], and they have been recog-
nized as multifunctional proteins similar to the lymphocyte
surfaceglycoproteinCD26(EC3.4.14.5).DPPIVactivitywas
detected in Mφs[ 2] and only recently the subcellular frac-
tionation of other leukocyte types has localized the prepon-
derance of DPP8/9 protein to the cytosol and canonical EC
3.4.14.5inthemembranefractions[31].Basedonthatstudy,
we can speculate that DPPIV activity in the soluble frac-
tion of murine Mφs seems improbable to be EC 3.4.14.5, but
most likely DPP8/9, although the classical DPPIV inhibitor
diprotin A was eﬀective to decrease the DPPIV activity in
both S and M fractions of these cells [2]. Furthermore, since
these activities have not been puriﬁed from murine Mφs, it
remains to be investigated whether the changes in the DP-
PIV activity observed in the present study are accompanied
bycorrespondingchangesintherespectiveproteinormRNA
expression. In general, these proline-speciﬁc dipeptidyl pep-
tidases are unique among the aminopeptidases because of
their superimposed ability to liberate Xaa-Pro and less eﬃ-
ciently Xaa-Ala dipeptides from the N-terminus of regula-
tory peptides. DPPIV-like enzymes act on peptide degrada-
tion (e.g., peptide hormone, various cytokines and growth
factors), amino acid scavenging, cell-to-cell communication,
signal transduction and adhesion, and as a receptor as well
[30].Recently,wehavereportedthatCsAhasnoeﬀectonba-
sic and neutral aminopeptidase activities of TGE Mφs[ 32].
Here we evidenced that CsA has also no eﬀect on DPPIV ac-
tivity, but produced a reduction on POP activity levels in the
proinﬂammatory model of TGE Mφs.POPis known as post-
proline cleaving enzyme activity, TRH-deaminaseactivity, or
kininase B activity. The link between POP enzyme and in-
ﬂammatory or autoimmune syndromes has been evidenced
in some studies. In a mouse model of systemic lupus erythe-
matosus, POP activity is increased in the spleen of diseased
subjectswhencomparedtocontrols.Thisincreaseisprogres-
sive with age and indicates that POP plays an important role
in the immunopathological disturbances associated with this
syndrome [33, 34]. Other links between POP and immuno-
logical disturbances were made when increased POP levels
in synovial membrane preparations from patients suﬀering
from rheumatoid arthritis were observed and it is also sug-
gested that POP may play a signiﬁcant role in the onset of
osteoarthrosis [35, 36]. POP cleaves Pro-Xaa bonds in pep-
tides that consist of an acyl-Yaa-Pro-Xaa sequence as found
in nociceptive mediators such as bradykinin and substance P
[37, 38], which can also be considered a link between inﬂam-
mationandpain.Ithasbeenreportedthataberrantpainper-
ception and depressive symptoms in ﬁbromyalgia are related
to lower serum POP activity [39]. On the other hand, litera-
ture data about eﬀects of CsA on nociception are controver-
sial.AcuteadministrationofCsAhasbeenreportedtoreduce
corticotropin-releasing factor-induced peripheral antinoci-
ception through eﬀects on opioid-containing immune cells
[40]. Headache symptoms in patients receiving CsA for or-
gan transplantation have been connected with an endothe-
lial dysfunction related to increased production of nitric ox-
ide [41]. CsA has also been implicated in severe leg pain in
patients with psoriatic arthritis [42]. Conversely, acute ad-
ministrationofCsAhasbeenreportedtoinduceanantinoci-
ceptive eﬀect that involves the L-arginine-oxid nitric path-
way,whichis notmediated by opioid receptors [43],andalso
reduced inﬂammatory joint hyperalgesia in rat adjuvant-
induced arthritis [44]. Moreover, it was reported that CsA
can induce antinociception and increased plasma levels of
met-enkephalin [45]. A possible explanation for these con-
traditoryﬁndingsisthatanalgesicoralgesicactionsandtheir
intensities vary according to prevalent cell types and mech-
anisms related to diﬀerent pain stimuli and/or therapy regi-
men with CsA. Processes of sensitization (spontaneous pain
and augmented pain response on noxious stimulation, and
pain on normally nonpainful stimulation) are common in
chronic peripheral inﬂammatory process such as arthritis,
which has been currently treated with MTX and/or CsA [46–
49]. This sensitization seems to involve bradykinin binding
to nerve ﬁbers receptors, while the expression of these recep-
tors is upregulated during inﬂammation. In this turn, sub-
stance P promotes subsequent central sensitization to that
produced by glutamate on spinal cord neurons [50]. How-
ever, at nerve ﬁber receptor level, the control of these medi-
ators by enzymatic cleavage has not been investigated. Taken
together, literature data, the eﬀectiveness of immunosup-
pressive response to CsA on day 21 [23], and our data show-
ing concomitant reduction of TGE Mφ POP activity and tol-
erance to thermally-induced algesia by CsA, suggest a rela-
tionship between the observed eﬀects of CsA on these proin-
ﬂammatorycellsandonthe availabilityofbradykinin and/or
substance P at receptor level of nerve ﬁbers. Since MTX or
MTX plus CsA increased POP activity but did not change
the reaction to the same algesic stimulus, it is likely that be-
sides POP activity other pain mediators are altered by the
adopted treatment with CsA. Alternatively, only the reduc-
tion of POP activity below a critical level, as demonstrated
here in the proinﬂammatory model of murine Mφs, could be
related to hyperalgesia. It is also conceivable that murine Mφ
POP can potentially be a novel POP enzyme, since POP ac-
tivity in murine Mφs was inhibited by classical aminopepti-
daseinhibitors[2]and,asdemonstratedinthepresentstudy,
by the classical POP inhibitor Z-pro-prolinal, at well-known
eﬀective concentrations [51]. Furthermore, residual Z-pro-
prolinal-resistant POP activity in Mφs and in bovine serum
could be similar [51]. To clarify these points, the identiﬁca-
tion of Mφ POP protein and the eﬀects on algesia using a
selective inhibitor of Mφ POP activity need further investi-
gations.
In conclusion, our data indicate the participation of two
representative prolyl peptidases in murine Mφs within the
eﬀects of MTX and/or CsA treatment, and provide scope for8 Clinical and Developmental Immunology
additionalstudiesonthemechanismofactionandeﬃcacyof
individual or combined therapy with both drugs in painful
and inﬂammatory diseases.
ABBREVIATIONS
BSA: Bovine serum albumin.
CsA: Cyclosporine A
DPPIV: Dipeptidyl peptidase IV
DTT: Dithiothreitol
IFN gamma: Interferon-gamma
IL: Interleukin
LDH: Lactate dehydrogenase
M: Membrane-bound
MHC: Major histocompatibility complex
Mφ:M a c r o p h a g e
MTX: Methotrexate
NADH: Nicotinamide adenine dinucleotide reduced
form
POP: Prolyl oligopeptidase
RE: Resident
S: Soluble
SNK: Student-Newman-Keuls test
TG: Thioglycollate broth medium
TGE: Thioglycollate broth medium-elicited
TNF alpha: Tumor necrosis factor-alpha
UP: Picomoles of substrate hydrolyzed per
minute
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